Skip to main navigation
Skip to search
Skip to main content
Ben-Gurion University Research Portal Home
Help & FAQ
Link opens in a new tab
Search content at Ben-Gurion University Research Portal
Home
Profiles
Research output
Research units
Prizes
Press/Media
Student theses
Projects
Activities
Datasets
Research Labs
Etoposide and cisplatin for non-small cell lung cancer
David B. Geffen
, Sofia Man
,
Yoram Cohen
Internal Medicine Division
Research output
:
Contribution to journal
›
Article
›
peer-review
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Etoposide and cisplatin for non-small cell lung cancer'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Cisplatin
100%
Etoposide
100%
Non-small Cell Lung Cancer (NSCLC)
100%
Disease Stage
20%
New Drugs
20%
In(III)
20%
Renal Failure
20%
Radiation Therapy
20%
Cancer Center
20%
Chemotherapy
20%
Metastatic Disease
20%
Neutropenic Fever
20%
Median Survival
20%
First-line Chemotherapy
20%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
20%
Stage III Disease
20%
Locally Advanced Stage
20%
Medicine and Dentistry
Cisplatin
100%
Etoposide
100%
Non Small Cell Lung Cancer
100%
Malignant Neoplasm
16%
Renal Failure
16%
Metastatic Carcinoma
16%
Febrile Neutropenia
16%
First-Line Chemotherapy
16%
Diseases
16%
Chemotherapy
16%
Radiation Therapy
16%
Pharmacology, Toxicology and Pharmaceutical Science
Cisplatin
100%
Etoposide
100%
Non Small Cell Lung Cancer
100%
Malignant Neoplasm
16%
Kidney Failure
16%
Febrile Neutropenia
16%
Chemotherapy Regimens
16%
First-Line Chemotherapy
16%
Diseases
16%